ECA

AstraZenca to cut 1,150 US sales positions

Wednesday, December 7, 2011 01:56 PM

AstraZeneca will reduce its U.S. sales force by approximately 1,150 leadership positions and sales representatives as part of the company’s ongoing strategy to operate its business more efficiently to best serve patients in the United States.

More... »

AstraZeneca, MRC ink collaboration giving UK academia access to 22 compounds

Monday, December 5, 2011 02:14 PM

A wide range of compounds will be made available free of charge to UK medical researchers next year, following an agreement between the Medical Research Council (MRC) and AstraZeneca. Academia will be granted access to 22 compounds, developed by AstraZeneca. Through MRC funding, UK academia will conduct studies to better understand what drives a range of diseases with a view to exploring new treatment opportunities.

More... »

AstraZeneca, Cognizant sign multi-year agreement

Wednesday, November 30, 2011 11:10 AM

More... »

AstraZeneca commits additional $100m to MedImmune

Tuesday, November 29, 2011 02:22 PM

AstraZeneca has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.

More... »

U-M Medical School, MedImmune ink 3 year research agreement

Wednesday, November 23, 2011 09:42 AM

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects. The three-year strategic collaboration will bring scientists from one of the nation’s top medical research institutions together with scientists from one of the world’s leading developers of biologic therapies. UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

More... »

AgonOx, MedImmune partner to develop cancer therapies

Monday, October 31, 2011 11:57 AM

AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

More... »

AstraZeneca cuts hundreds of jobs in US

Friday, October 7, 2011 02:46 PM

AstraZeneca will streamline portions of its U.S. commercial business as part of the company's strategy to operate its business more effectively and efficiently to best serve patients in the United States. The changes will enable the company to compete in a challenging environment, including pricing pressures and the continuing growth of generic medicines.

More... »

AcelRx names Edwards to board of directors

Wednesday, September 28, 2011 11:55 AM

AcelRx Pharmaceuticals has named Mark G. Edwards to its board of directors. Edwards will also serve as the chairman of the audit committee.

More... »

AstraZenca seeks partners in China

Friday, September 23, 2011 02:28 PM

AstraZeneca will continue its cooperation model on research and development (R&D) in China instead of merger and acquisition (M&A), the company's executive said, according to China Daily.

More... »

Trizzino joins Immunovaccine as CEO

Monday, September 12, 2011 12:44 PM

Immunovaccine has named John J. Trizzino chief executive officer, effective October 1, 2011. Trizzino will also be appointed to the company's board of directors.

More... »